Immix Biopharma (NASDAQ:IMMX) Price Target Raised to $15.00

Immix Biopharma (NASDAQ:IMMX) had its price objective upped by Mizuho from $14.00 to $15.00 in a research note issued to investors on Monday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other brokerages also recently weighed in on IMMX. Morgan Stanley assumed coverage on Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Citizens Jmp reiterated a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a report on Friday, March 27th. HC Wainwright increased their price objective on Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Immix Biopharma Price Performance

Shares of IMMX opened at $8.62 on Monday. The company has a market capitalization of $456.60 million, a PE ratio of -9.69 and a beta of 0.20. Immix Biopharma has a one year low of $1.34 and a one year high of $11.61. The company’s fifty day moving average price is $8.01 and its 200 day moving average price is $5.40.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). Analysts anticipate that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors have recently added to or reduced their stakes in IMMX. Allworth Financial LP bought a new position in Immix Biopharma during the fourth quarter valued at about $30,000. Velan Capital Investment Management LP bought a new stake in shares of Immix Biopharma in the 2nd quarter worth approximately $52,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma during the 4th quarter worth approximately $56,000. Balyasny Asset Management L.P. acquired a new stake in shares of Immix Biopharma during the 4th quarter worth approximately $67,000. Finally, Kera Capital Partners Inc. bought a new stake in shares of Immix Biopharma during the fourth quarter valued at approximately $68,000. 11.26% of the stock is owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.